TBX2 and prostate cancer: Similarly, CD82 of sEVs in the serum of prostate cancer patients was shown to promote the expression of TBX2 (a tumor suppressor protein) and P21 (a cell cycle inhibitory enzyme), thereby reducing the primary tumor formation foci and ultimately inhibiting the proliferation and migration of prostate cancer cells (55).